12 August 2021: Leading Animal Healthcare company, Hester Biosciences Ltd reported a standalone net profit of Rs. 12.24 crore for the Quarter ended June 2021 as against net profit of Rs. 7.62 crore in the corresponding period last year – growth of 60%. Revenue from Operations for the Q1FY22 was reported at Rs. 58.51 crore, growth of 50% as compared to Revenue of Rs. 38.88 crore in the corresponding period last year. EPS for Q1FY22 was reported at Rs. 14.38 per share.
The Company achieved an improved operational and financial performance in Q1 FY22 as compared to the corresponding quarter of FY21. EBITDA Margin was reported at 31.02% and Net Profit margin at 20.92% in Q1FY22.The market and economic recovery has supported well for the growth of the poultry and animal industry and is expected to continue in the coming period. The company is constantly investing in the geographical market expansion and marketing manpower to achieve the budgeted topline.
The results of Q1 FY22 have been in line with the financial forecasts and the budgets
· During Q1 FY22, the overall topline grew by 50%, compared to Q1FY21 which was affected by a nationwide lockdown during the initial period of the pandemic.
· Overall, the sales of Vaccines have registered a growth of 41% in Q1 FY22, and the sale of Health Products have registered a growth of 94% in Q1 FY22.
· Domestic sales have registered a growth of 61% in Q1 FY22. The opening up of the domestic market has resulted in the higher demand of the products.
· Export sales have registered a marginal de-growth of 8% in Q1 FY22. Export orders are affected due to restricted cargo movements globally.
User :- Gopal Modi